Biogen Yönetim

Chris Viehbacher'un ücretlendirmesi Biogen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$4m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$30m	US$154k	US$3b

Tazminat ve Piyasa: Chris's total compensation ($USD4.07M) is below average for companies of similar size in the US market ($USD12.87M).

Tazminat ve Kazançlar: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Viehbacher (63 yo)

2yrs

Görev süresi

US$4,069,913

Tazminat

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Viehbacher	President	2yrs	US$4.07m	0.0048% $ 1.2m
Michael McDonnell	Executive VP & CFO	4.3yrs	US$7.17m	0.013% $ 3.4m
Nicole Murphy	Head of Pharmaceutical Operations & Technology	2.8yrs	US$5.71m	0.0066% $ 1.7m
Susan Alexander	Executive VP & Chief Legal Officer	18.8yrs	US$6.70m	0.035% $ 9.0m
Rachid Izzar	Head of Global Product Strategy & Commercialization	3.8yrs	US$5.45m	0.0067% $ 1.7m
Robin Kramer	Senior VP & Chief Accounting Officer	6yrs	Veri yok	0.0043% $ 1.1m
Stephen Amato	Head of Investor Relations	less than a year	Veri yok	Veri yok
Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	4.8yrs	Veri yok	Veri yok
Adam Keeney	Executive VP & Head of Corporate Development	1.6yrs	Veri yok	0.00045% $ 114.0k
Ginger Gregory	Executive VP & Chief Human Resources Officer	7.3yrs	US$5.08m	0.0093% $ 2.4m
Alisha Alaimo	President & Head of North America	7.3yrs	Veri yok	Veri yok
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	7.3yrs	Veri yok	Veri yok

4.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: BIIB's management team is considered experienced (4.5 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Viehbacher	President	2yrs	US$4.07m	0.0048% $ 1.2m
Stephen Sherwin	Independent Director	14.7yrs	US$435.32k	0.013% $ 3.3m
William Hawkins	Independent Director	5.4yrs	US$425.73k	0.0044% $ 1.1m
Caroline Dorsa	Independent Chair of the Board	14.8yrs	US$646.13k	0.017% $ 4.3m
Eric Rowinsky	Independent Director	14.7yrs	US$418.02k	0.014% $ 3.6m
Maria Freire	Independent Director	3.4yrs	US$412.90k	0.0031% $ 772.4k
Lloyd Minor	Directors	less than a year	Veri yok	Veri yok
Monish Patolawala	Independent Director	less than a year	Veri yok	0.00092% $ 233.0k
Jesus Mantas	Independent Director	5.4yrs	US$433.23k	0.0051% $ 1.3m
Susan Langer	Independent Director	1.4yrs	US$334.53k	0.0019% $ 478.6k

4.4yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BIIB's board of directors are considered experienced (4.4 years average tenure).

Biogen Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Recent updates

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Stock: Cheapish, But With Few Growth Prospects

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Pomerantz LLP Announces Filing of a Class Action against Biogen Inc

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Full year 2023 earnings: EPS misses analyst expectations

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 11%

Biotech And Pharma Diversification Pays Off

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 23%

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

CEO Tazminat Analizi

CEO